Yuan Ji, PhD
Yuan Ji, PhD
Verified email at uchicago.edu - Homepage
Cited by
Cited by
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells
M Sun, Z Estrov, Y Ji, KR Coombes, DH Harris, R Kurzrock
Molecular cancer therapeutics 7 (3), 464-473, 2008
Pan-cancer analysis of whole genomes
I The, TPCA of Whole, Genomes Consortium
Nature 578 (7793), 82, 2020
TCGA-assembler: open-source software for retrieving and processing TCGA data
Y Zhu, P Qiu, Y Ji
Nature methods 11 (6), 599-600, 2014
MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, Oncotype DX, and PAM50 gene assays
H Li, Y Zhu, ES Burnside, K Drukker, KA Hoadley, C Fan, SD Conzen, ...
Radiology 281 (2), 382-391, 2016
The evolutionary history of 2,658 cancers
M Gerstung, C Jolly, I Leshchiner, SC Dentro, S Gonzalez, D Rosebrock, ...
Nature 578 (7793), 122-128, 2020
Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set
H Li, Y Zhu, ES Burnside, E Huang, K Drukker, KA Hoadley, C Fan, ...
NPJ breast cancer 2 (1), 1-10, 2016
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
A Younes, Y Oki, RG Bociek, J Kuruvilla, M Fanale, S Neelapu, ...
The lancet oncology 12 (13), 1222-1228, 2011
Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics
JA Gilbert, OE Salavaggione, Y Ji, LL Pelleymounter, BW Eckloff, ...
Clinical Cancer Research 12 (6), 1794-1803, 2006
A modified toxicity probability interval method for dose-finding trials
Y Ji, P Liu, Y Li, B Nebiyou Bekele
Clinical trials 7 (6), 653-663, 2010
Synchronous selection of homing peptides for multiple tissues by in vivo phage display
MG Kolonin, J Sun, KA Do, CI Vidal, Y Ji, KA Baggerly, R Pasqualini, ...
The FASEB Journal 20 (7), 979-981, 2006
Bayesian dose‐finding in phase I/II clinical trials using toxicity and efficacy odds ratios
G Yin, Y Li, Y Ji
Biometrics 62 (3), 777-787, 2006
Applications of beta-mixture models in bioinformatics
Y Ji, C Wu, P Liu, J Wang, KR Coombes
Bioinformatics 21 (9), 2118-2122, 2005
Glycine and a Glycine Dehydrogenase (GLDC) SNP as Citalopram/Escitalopram Response Biomarkers in Depression: Pharmacometabolomics‐Informed …
Y Ji, S Hebbring, H Zhu, GD Jenkins, J Biernacka, K Snyder, M Drews, ...
Clinical Pharmacology & Therapeutics 89 (1), 97-104, 2011
Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma
E Pectasides, MD Stachler, S Derks, Y Liu, S Maron, M Islam, L Alpert, ...
Cancer discovery 8 (1), 37-48, 2018
Modified toxicity probability interval design: a safer and more reliable method than the 3+ 3 design for practical phase I trials
Y Ji, SJ Wang
Journal of Clinical Oncology 31 (14), 1785, 2013
Deciphering genomic underpinnings of quantitative MRI-based radiomic phenotypes of invasive breast carcinoma
Y Zhu, H Li, W Guo, K Drukker, L Lan, ML Giger, Y Ji
Scientific reports 5 (1), 1-10, 2015
Dose-finding in phase I clinical trials based on toxicity probability intervals
Y Ji, Y Li, B Nebiyou Bekele
Clinical trials 4 (3), 235-244, 2007
Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data
W Guo, H Li, Y Zhu, L Lan, S Yang, K Drukker, EA Morris, ES Burnside, ...
Journal of medical imaging 2 (4), 041007, 2015
Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a …
Y Ji, JM Skierka, JH Blommel, BE Moore, DL VanCuyk, JK Bruflat, ...
The Journal of Molecular Diagnostics 18 (3), 438-445, 2016
Phase II study of yttrium-90–ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma
M Wang, Y Oki, B Pro, JE Romaguera, MA Rodriguez, F Samaniego, ...
Journal of clinical oncology 27 (31), 5213-5218, 2009
The system can't perform the operation now. Try again later.
Articles 1–20